Considering the current exploratory attempts to use PARP inhibitors in gastric cancer treatment [90], the addition of a PARP inhibitor (such as olaparib) to oxaliplatin chemotherapy for FGFR4-Arg388 gastric cancer patients is worth investigating. This evidence concerns the gene FGFR4 and gastric cancer.